Endometriosis Treatment – Increased Awareness among People and Growing Treatment-Seeking Rate
Increasing awareness among the general population as well as physicians regarding endometriosis, and the increasing diagnosis rate and treatment-seeking rate for endometriosis conditions are among factors expected to boost the endometriosis treatment market. Companies are coming up with major branding, launching new products, and reducing the costs of their product offerings to reach out to people who are likely to be suffering from endometriosis conditions.
Top 3 Factors Shaping the Endometriosis Treatment Market
Discovery of novel drug types due to technological advancements
Increase in the number of endometriosis cases and awareness has led to a number of new drugs being held under the research phase for endometriosis. Selective oestrogen receptor modulators, such as Raloxifene, are among the new sets of medications that are effective in case studies because of their anti-oestrogen effect. Other immune modulators in the research phase that are marked as potential therapies for endometriosis include interferon-alpha-2b, levamisole, interleukin-12, and loxoribine. New product launch is expected to trigger the endometriosis treatment market.
Global prevalence of endometriosis conditions is expected to drive the endometriosis treatment market
Endometriosis affects a large number of women in their reproductive phase. It is estimated to have a prevalence rate of 1 in 10 women in the reproductive phase. Increase in the number of women of reproductive age suffering from endometriosis is among the key factors boosting the endometriosis treatment market. In addition, the prevalence of endometriosis is not subject to any illness, and takes place during the menstrual cycle. Although there is no cure for endometriosis, effective treatment can be delivered through medication, which suppresses the pain caused by endometriosis. Number of prevalent population in developing regions are not stated, awareness and understanding different scale of pain is very limited in regions and often gets ignored. The situation is not only seen in developing or low economic countries, but also in developed nations such as UK, where it is assumed that approximately 2 million women are undiagnosed with endometriosis conditions.
Use of GnRH analogues for endometriosis treatment is expected to fuel the growth of the endometriosis treatment market
GnRH analogues are generally prescribed as the second line of treatment for endometriosis conditions, and physicians commonly recommend GnRH analogues for six months. Like other medications, the exposure of GnRH analogues is limited because of their high prices as compared to oral contraceptives. Though the product is gaining traction from manufacturers end, as the biggest product for endometriosis treatment which got FDA approval is elagolix, brand name Orilissa, it is a gonadotropin-releasing hormone antagonist (GnRH antagonist). This drug is estimated to grow the market share of GnRH analogues in endometriosis treatment market as it is the only available drug type. Manufacturers are focusing on hormone therapy, where the result is comparatively higher than most other pain management medications, and leading to more no. of consumers to prefer that option.
Endometriosis Treatment Market Structure Analysis
- The global endometriosis treatment market is a consolidated market owing to the presence of major market players
- Some of the prominent companies in the endometriosis treatment market include Bayer AG, AbbVie Inc., AstraZeneca PLC, Pfizer Inc., Ipsen Pharma, Myovant Sciences Ltd, Endoceutics, Inc., Debiopharm Group, and Teva Pharmaceutical Industries Ltd.
- Most of the key players are emphasizing on collaborations and mergers to strengthen their market share and long-term competitive position
- The companies are focusing on investing in R&D for the development of innovative products and new launches
- Some of the top manufacturers that contribute a high revenue share in the endometriosis treatment market are Bayer AG, AbbVie Inc., and AstraZeneca Plc
Endometriosis Market Set to Grow by 1.3X between 2018 and 2028
Product diversification in different economies, growing adoption of other alternative treatment for the condition which continue to augur well for the Endometriosis Treatment landscape. Great opportunity for the manufactures to involve in the awareness campaigns, public events and collaboration with the government and other organisations which is expected to fuel the Endometriosis Treatment market.
Stakeholders Vie to Tap Opportune Potential of Emerging Markets
Growing prevalence of Endometriosis condition and need for generic injectables & drugs as well as personalized therapy in emerging markets is expected to create huge opportunity for the manufacturer. Western Europe continues to lead the endometriosis treatment landscape, with sales growing at a relatively higher rate.
* This data is only a representation. Actual data may vary and will be available in report.
The Broader Perspective
The manufacturers of endometriosis treatment products are focusing on increasing their market share in the Asia Pacific region through mergers and acquisitions with regional or local players as well as investment groups. In addition, manufacturers are focusing on forward integration with partnerships with wholesalers, distributors, and other channel partners to gain ownership over the value chain.
Oral contraceptives remain the top-selling variant with a share of over 45%.
The sales of GnRH analogues are expected to grow at a higher rate among other drug types
Adoption of the LNR-IUDs drug type is expected to remain low during the forecast period.
Hormonal therapy remains the most lucrative category, accounting for a market share of over 80%.
Pain management is likely to witness slow growth.
Hospital pharmacies continue to lead the endometriosis treatment landscape due to an increasing treatment-seeking rate, especially in developed countries.
Retail pharmacies also account for a notable share of the market.
Demand is expected to grow at a significant rate in the e-commerce segment.
How Growth will Unfold
contraceptives are are being administered orally are expected to account for a leading share of the endometriosis treatment market by drug type, owing to their high adoption, coupled with the increasing incidence of chronic conditions and the availability of limited treatment options. The development of novel hormonal therapies due to the higher benefits offered by analgesics is expected to fuel the growth of the endometriosis treatment market.
Hospital Pharmacies | Retail Pharmacies | Drugstores | E-commerce
* This data is only a representation. Actual data may vary and will be available in report.Click Here To Know How The Growth Will Unfold
Custom Market Research Services
FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.
Endometriosis Treatment Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028
A recent market study published by FMI “Endometriosis Treatment Market: Global Industry Analysis 2013–2017 and Forecast 2018–2028” offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historic as well as current growth parameters of the endometriosis treatment market, the growth prospects of the market are obtained with maximum precision.
Endometriosis Treatment Market Taxonomy
The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.
By Drug Type
- Oral Contraceptives
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- GnRH Analogues
By Treatment Type
- Hormonal Therapy
- Pain management
By Distribution Channel
- Hospital pharmacies,
- Retail pharmacies,
- North America
- Latin America
- Eastern Europe
- Western Europe
- Middle East & Africa
The report commences with the executive summary of the endometriosis treatment market report, which includes a summary of the key findings and key statistics of the market. It also includes the market value (US$ million) for leading segments in the endometriosis treatment market.
Readers can find a detailed market structure and definition of endometriosis treatment and drug types, in this chapter, which helps in understanding the basic information about the endometriosis treatment market. The definition section considers the factors included and excluded for the purpose of this report.
Readers can find the outlook of the global endometriosis treatment market, considering various factors associated with the growth, which would help in tracking the market’s current scenario, with key inferences drawn from historical data, current trends, and future prospects. Macro-economic factors influencing the market are also discussed in this segment. A brief understanding of the global healthcare sector is also provided in this section.
This chapter highlights the key market dynamics, including drivers, restraints, opportunities, and trends. In this chapter, readers can understand factors that are propelling the growth of the market, along with factors that may deter the growth of the market. Also, readers will understand the key trends followed by leading manufacturers in the endometriosis treatment market.
Key pointers such as pipeline drug analysis and new medical treatments for endometriosis are also included in this endometriosis treatment market report.
This chapter includes detailed analysis of the growth of the North America endometriosis treatment market, along with a country-wise assessment of the U.S. and Canada. Readers can also find historical trends and market attractiveness based on drug type, treatment type, distribution channel, and country in the North American region.
This chapter includes detailed analysis of the growth of the Latin America endometriosis treatment market, along with a country-wise assessment, including Brazil and Mexico. Market attractiveness based on various segments is provided for the Latin American region.
Important growth prospects of the endometriosis treatment market can be found with market attractiveness based on drug type, treatment type, and distribution channel. European countries such as Germany, France, Italy, Spain, and the U.K. are included in this chapter for industry analysis.
This chapter includes detailed analysis of the growth of the Eastern Europe endometriosis treatment market, along with a country-wise assessment, including Russia and Poland. Market attractiveness based on various segments is provided for the Eastern European region.
India, Australia & New Zealand, and Japan are the leading countries/regions in the Asia Pacific region that are assessed to obtain the growth prospects of the APEC endometriosis treatment market in this chapter. Readers can find thorough information about the growth parameters. Market attractiveness based drug type, treatment type, and distribution channel for endometriosis treatment in the APEC region is also provided in this section.
This chapter includes detailed analysis of the growth of the China endometriosis treatment market. Market attractiveness based drug type, treatment type, and distribution channel is present for this region
This chapter provides information on how the endometriosis treatment market will grow in major countries of the MEA region, such as GCC Countries and South Africa, during the period 2018-2028.
This chapter provides forecast factors for relevance in building the market value for the endometriosis treatment market
This chapter includes a comprehensive list of all the leading manufacturers in the endometriosis treatment market, along with detailed information about each company, including company overview, revenue share, strategic overview, and recent company developments. Market players featured in the report include AbbVie Inc., Bayer AG, AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Ipsen Pharma, Myovant Sciences Ltd, Endoceutics, Inc., Debiopharm Group and Mayne Pharma Group Limited
This section highlights endometriosis treatment in the overall global market by value (US$ Mn) forecast and analysis, by region.
Based on drug type market analysis, the endometriosis treatment market is segmented into oral contraceptives, progestins, NSAIDs, GnRH analogues, LNR-IUDs, and others.
Based on distribution channel, the endometriosis treatment market is segmented into hospital pharmacies, retail pharmacies, drugstores, and e-Commerce.
This section highlights the overall global market value (US$ Mn) forecast and analysis of the endometriosis treatment market, with detailed incremental opportunity and absolute opportunity.
This section consists of a glossary of the assumptions and acronyms used in the endometriosis treatment market report.
This chapter helps readers understand the research methodology that is followed to obtain various conclusions, important qualitative information, and quantitative information about the endometriosis treatment market.
How the research was conducted?
Primary research interview with Key Opinion Leaders and other participants were conducted for data collection and validation of the below information:
- High Prevalence by Gender and Age-Group
- Treatment Seeking Rate
- Adoption of Non-steroidal anti-inflammatory drugs injection as mode of treatment
- Average Dosage Pattern per Patient
- Average Selling Price (US$) and Market Growth
- Key Developments
- Key Trends and Opportunities
- Regional wise Dynamics
- Reimbursement Landscape
- Market Share Information
- Key Brands
- Competition & Key Vendor Strategies
- Jean Hailes
- Endometriosis UK,
- American College of Obstetricians and Gynecologists
- Endometriosis Australia
- ENDOMETRIOSIS FOUNDATION OF AMERICA
- American Pregnancy Association
- National Institute of Child Health and Human Development
- The National Women’s Health Information Center
- Royal College of Obstetricians and Gynecologists
- Endometriosis Association, Inc.
- Boston Center for Endometriosis
- Endometriosis Research Center
- American Society for Reproductive Medicine
- National Women’s health Network (NWHN)
- Society of Endometriosis and Uterine Disorders
- Endometriosis New Zealand Ltd.
- Annual Reports/SEC filings/Investor Presentations/Earning Call Transcript
- Industry Journals
Primary Interview Splits
Endometriosis Treatment Market Reports - Table of Contents
13. Forecast Factors: Relevance and Impact
20. Assumptions and Acronyms Used
21. Research Methodology